Report for: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)

Title	Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)
Published in	Trials, July 2022
DOI	10.1186/s13063-022-06533-0
Pubmed ID	35869526
Authors	Tania Smith, Carlos Hoyo-Vadillo, Akosua Agyeman Adom, Liliana Favari-Perozzi, Silke Gastine, Hakim-Moulay Dehbi, Beatriz Villegas-Lara, Eduardo Mateos, Yessica Sara Pérez González, Maria D. Navarro-Gualito, Alejandra S. Cruz-Carbajal, Miguel A. Cortes-Vazquez, Carolina Bekker-Méndez, Charmina Aguirre-Alvarado, Gisela Aguirre-Gil, Lucero Delgado-Pastelin, Andrew Owen, David Lowe, Joseph Standing, Jorge Escobedo

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
United States	1	25%
Unknown	3	75%

Type	Count	As %
Members of the public	4	100%

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	36	100%

Readers by professional status	Count	As %
Student > Master	3	8%
Researcher	2	6%
Student > Doctoral Student	1	3%
Student > Bachelor	1	3%
Lecturer	1	3%
Other	4	11%
Unknown	24	67%

Readers by discipline	Count	As %
Medicine and Dentistry	5	14%
Pharmacology, Toxicology and Pharmaceutical Science	2	6%
Nursing and Health Professions	2	6%
Social Sciences	1	3%
Environmental Science	1	3%
Other	2	6%
Unknown	23	64%

Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)